Literature DB >> 17999183

Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer.

Wei-Guo Dong1, Qiong-Fang Yu, Yu Xu, Li-Fang Fan.   

Abstract

The aims of this study were to examine the expressions of Li-cadherin and Galectin-3 in gastric cancer, and the correlation between Li-cadherin and Galectin-3 in gastric cancer was also analyzed. The present study investigated the expression level of Li-cadherin and Galectin-3 by immunohistochemistry and semiquantitative polymerase chain reaction (PCR), and correlated this with clinicopathologic parameters in 91 cases of gastric cancer. The correlation between expression levels of Li-cadherin and Galectin-3 was analyzed by Spearman correlation analysis. The expression level of Li-cadherin mRNA was correlated to differentiation and lymph node metastasis, and the expression level of Galectin-3 was related to TNM staging, differentiation and lymph node metastasis. On Spearman correlation analysis, a definitive negative correlation was found between the expression levels of Li-cadherin and Galectin-3 in gastric cancerous tissues. We postulate that interaction between Li-cadherin and Galectin-3 may play an important role in the development of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999183     DOI: 10.1007/s10620-007-0080-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

Review 1.  Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.

Authors:  Zi-Wen Long; Meng-Long Zhou; Jing-Wei Fu; Xian-Qun Chu; Ya-Nong Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Knockdown of Li-cadherin increases metastatic behaviors of LoVo cells.

Authors:  Qiong-Fang Yu; Wei-Guo Dong; Jian-Lin Ren
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.

Authors:  Jin Zhang; Qi-Sheng Liu; Wei-Guo Dong
Journal:  Med Oncol       Date:  2011-06       Impact factor: 3.064

Review 4.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

5.  Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients.

Authors:  Mariana Ferreira Leal; Danielle Queiroz Calcagno; Janete Chung; Vanessa Morais de Freitas; Samia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília Cardoso Smith
Journal:  Clin Exp Med       Date:  2014-07-18       Impact factor: 3.984

6.  Knockdown of liver-intestine cadherin decreases BGC823 cell invasiveness and metastasis in vivo.

Authors:  Yu Xu; Jin Zhang; Qi-Sheng Liu; Wei-Guo Dong
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

7.  Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.

Authors:  Anna Mokrowiecka; Sarah Zonnur; Lothar Veits; Jacek Musial; Radzislaw Kordek; Mariusz Lochowski; Jozef Kozak; Ewa Malecka-Panas; Michael Vieth; Arndt Hartmann
Journal:  Dig Dis Sci       Date:  2012-10-04       Impact factor: 3.199

Review 8.  Possible roles of LI-Cadherin in the formation and maintenance of the intestinal epithelial barrier.

Authors:  Werner Baumgartner
Journal:  Tissue Barriers       Date:  2013-01-01

9.  Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.

Authors:  Zhaohu Lin; Chao Zhang; Meifang Zhang; Danqing Xu; Yanfen Fang; Zheng Zhou; Xiaolong Chen; Ning Qin; Xiongwen Zhang
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

10.  Expression of galectin-3 in gastric adenocarcinoma.

Authors:  Thiago Simño Gomes; Celina Tizuko Fujiyama Oshima; Nora Manoukian Forones; Flávio De Oliveira Lima; Daniel Araki Ribeiro
Journal:  Indian J Med Res       Date:  2014-07       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.